Advertisement
Advertisement
SNDX
Syndax Pharmaceuticals, Inc.
21.49
USDSponsored
+0.95
+4.63%
May 08, 16:00 UTC -4
Closed
After-Market
21.66
+0.18
+0.81%
SNDX Earnings Reports
Positive Surprise Ratio
SNDX beat 30 of 41 last estimates.
73%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$82.43M
/-$0.44
Implied change from Q1 26 (Revenue/ EPS)
+27.08%
/-8.33%
Implied change from Q2 25 (Revenue/ EPS)
+117.16%
/-46.99%
Syndax Pharmaceuticals, Inc. earnings per share and revenue
On Apr 30, 2026, SNDX reported earnings of -0.48 USD per share (EPS) for Q1 26, beating the estimate of -0.59 USD, resulting in a 19.15% surprise. Revenue reached 64.86 million, compared to an expected 71.85 million, with a -9.72% difference. The market reacted with a -10.83% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -0.44 USD, with revenue projected to reach 82.43 million USD, implying an decrease of -8.33% EPS, and increase of 27.08% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
FAQ
What were Syndax Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Syndax Pharmaceuticals, Inc. reported EPS of -$0.48, beating estimates by 19.15%, and revenue of $64.86M, -9.72% below expectations.
How did the market react to Syndax Pharmaceuticals, Inc.'s Q1 2026 earnings?
The stock price moved down -10.83%, changed from $21.43 before the earnings release to $19.11 the day after.
When is Syndax Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Syndax Pharmaceuticals, Inc.'s next earnings report?
Based on 8
analysts, Syndax Pharmaceuticals, Inc. is expected to report EPS of -$0.44 and revenue of $82.43M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement